Evidence map›Paper›PMID 41955551›Full record

ArticleJCO precision oncology2026

Clinicogenomic Landscape and Function of

Jacqueline J Tao, Saumya D Sisoudiya, Hanna Tukachinsky, Alexa B Schrock, Ericka M Ebot, Smruthy Sivakumar, Ethan S Sokol, Neil Vasan

Abstract read
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The journal of liquid biopsy · 2026
    Review
  2. Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jacqueline J TaoColumbia University Irving Medical Center, New York, NY.ORCID 0000-0003-1806-1269
Saumya D SisoudiyaFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0001-7276-8084
Hanna TukachinskyFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0002-0777-7555
Alexa B SchrockFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0003-0106-9096
Ericka M EbotFoundation Medicine Inc, Cambridge, MA.
Smruthy SivakumarFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0001-7790-5615
Ethan S SokolFoundation Medicine Inc, Cambridge, MA.ORCID 0000-0002-2988-0537
Neil VasanDepartment of Medicine, New York University Grossman School of Medicine, New York, NY.ORCID 0000-0003-1779-484X

Funding

Investigating a hierarchical model for PI3K activation and inhibition in breast cancer by double PIK3CA mutations in cisK08CA245192 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI VASAN, NEIL · 2020 to 2024
$1.2M
NCI NIH HHS K08 CA245192
6 · The paper itself

Abstract

purposeTo comprehensively characterize the clinical and genomic landscapes of

methodsComprehensive genomic profiling of 51,767 breast tumors was performed using FoundationOne CDx or FoundationOne. We examined the genomic landscape of

resultsA total of 29,157 variants were identified across the three genes, including pathogenic variants and variants of uncertain significance. The most frequently altered gene was

conclusionHere, we present the landscape of

Indexed as

Breast NeoplasmsClass I Phosphatidylinositol 3-KinasesMutationProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseFemaleFulvestrantHumansMiddle AgedPyrimidinesPyrrolesAKT1 protein, humancapivasertibClass I Phosphatidylinositol 3-KinasesFulvestrantPIK3CA protein, humanProto-Oncogene Proteins c-aktPTEN PhosphohydrolasePTEN protein, humanPyrimidinesPyrroles

Identifiers

PMID41955551
PMCPMC13086116

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.